FDA warned Dermal Source that five topical anesthetic products are unapproved and misbranded drugs with lidocaine above OTC limits.
What happened
FDA reviewed Dermal Source's website in September 2023 and found five products sold as external pain-relief drugs for use before, during or after cosmetic procedures such as tattooing, piercing and laser/dermabrasion. FDA said the products are unapproved new drugs and misbranded because their lidocaine 5% strength and some "-caine" combinations do not meet FDA's over-the-counter (OTC) rule for external pain-relief drugs, and their labeling includes uses not covered by that rule. FDA also said these uses raise safety concerns because more drug may be absorbed through irritated or broken skin.
What FDA found
The five products are unapproved new drugs because they are marketed as external pain-relief drugs without an FDA-approved application and do not meet the OTC rule for such drugs.
FD&C Act section 505(a), 21 U.S.C. 355(a)The products are misbranded because they are nonprescription drugs that do not meet section 505G requirements and are not covered by an approved application.
FD&C Act section 502(ee), 21 U.S.C. 352(ee)The labels list lidocaine hydrochloride 5%, which is above the 0.5% to 4% range allowed by the OTC external analgesic rule.
OTC Monograph M017; FD&C Act section 505GSome products combine more than one "-caine" active ingredient, which the OTC external analgesic rule does not permit.
OTC Monograph M017The labeling claims use for tattooing, piercing, permanent makeup, laser/dermabrasion, or electrology, which are not indications included in the OTC external analgesic rule or another final order.
FD&C Act section 505G; OTC Monograph M017FDA cited safety concerns that these products may be applied to large areas of irritated or broken skin without trained health professional supervision, increasing absorption and risk of serious injury.
What FDA wants
Within 15 working days of receipt, notify FDA in writing of specific steps taken to address the violations, explain steps to prevent recurrence, and include related documentation. If Dermal Source believes the products are not in violation, it must send its reasoning and supporting information; if it cannot complete corrections in that time, it must state why and give a completion date.
Who should pay attention
- tattoo, piercing and permanent makeup studios and artists
- distributors and retailers of topical numbing products
- consumers undergoing cosmetic procedures using topical anesthetics
This is a summary. Read the original letter on fda.gov.